BIOT
NASDAQBiotech Acquisition Company
News · 26 weeks10%
2025-12-212026-06-14
Mix090d
No activity.
Latest news
25 items- SECSEC Form 424B3 filed by Biotech Acquisition Company424B3 - Relativity Holdings Inc. (0002072188) (Filer)
- SECSEC Form EFFECT filed by Biotech Acquisition CompanyEFFECT - Relativity Holdings Inc. (0002072188) (Filer)
- SECSEC Form POS AM filed by Biotech Acquisition CompanyPOS AM - Relativity Holdings Inc. (0002072188) (Filer)
- SECAmendment: SEC Form F-4/A filed by Biotech Acquisition CompanyF-4/A - Relativity Holdings Inc. (0002072188) (Filer)
- SECAmendment: SEC Form F-4/A filed by Biotech Acquisition CompanyF-4/A - Relativity Holdings Inc. (0002072188) (Filer)
- 13D/GSEC Form SC 13G/A filed by Biotech Acquisition Company (Amendment)SC 13G/A - Biotech Acquisition Co (0001825413) (Subject)
- SECSEC Form 15-12G filed by Biotech Acquisition Company15-12G - Biotech Acquisition Co (0001825413) (Filer)
- 13D/GSEC Form SC 13G/A filed by Biotech Acquisition Company (Amendment)SC 13G/A - Biotech Acquisition Co (0001825413) (Subject)
- 13D/GSEC Form SC 13G filed by Biotech Acquisition CompanySC 13G - Biotech Acquisition Co (0001825413) (Subject)
- 13D/GSEC Form SC 13G/A filed by Biotech Acquisition Company (Amendment)SC 13G/A - Biotech Acquisition Co (0001825413) (Subject)
- 13D/GSEC Form SC 13G/A filed by Biotech Acquisition Company (Amendment)SC 13G/A - Biotech Acquisition Co (0001825413) (Subject)
- SECSEC Form 25-NSE filed by Biotech Acquisition Company25-NSE - Biotech Acquisition Co (0001825413) (Subject)
- SECBiotech Acquisition Company filed SEC Form 8-K: Termination of a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - Biotech Acquisition Co (0001825413) (Filer)
- NEWSReported Late Wednesday, Biotech Acquisition Company Announces Liquidation; Will Not Implement The Extension Of The Time Period The Company Has To Complete An Initial Business CombinationBiotech Acquisition Company (the "Company") (NASDAQ:BIOT), announced today that it will not implement the extension of the time period the Company has to complete an initial business combination as approved by its shareholders at an extraordinary general meeting of shareholders held on January 19, 2023 as a result of the investor being unable to deposit the requisite funds into the Company's trust account ("Trust Account") for the extension. As a result, the Company will dissolve and liquidate in accordance with the provisions of its Amended and Restated Memorandum and Articles of Association, as amended (the "Charter") and will redeem all of the outstanding ordinary shares that were include
- PRBiotech Acquisition Company Announces LiquidationNew York, New York, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Biotech Acquisition Company (the "Company") (NASDAQ:BIOT), announced today that it will not implement the extension of the time period the Company has to complete an initial business combination as approved by its shareholders at an extraordinary general meeting of shareholders held on January 19, 2023 as a result of the investor being unable to deposit the requisite funds into the Company's trust account ("Trust Account") for the extension. As a result, the Company will dissolve and liquidate in accordance with the provisions of its Amended and Restated Memorandum and Articles of Association, as amended (the "Charter") and will redeem
- 13D/GSEC Form SC 13G filed by Biotech Acquisition CompanySC 13G - Biotech Acquisition Co (0001825413) (Subject)
- SECBiotech Acquisition Company filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Biotech Acquisition Co (0001825413) (Filer)
- 13D/GSEC Form SC 13G filed by Biotech Acquisition CompanySC 13G - Biotech Acquisition Co (0001825413) (Subject)
- SECBiotech Acquisition Company filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits8-K - Biotech Acquisition Co (0001825413) (Filer)
- NEWSReported Late Wednesday, Biotech Acquisition Company Announces Plan For New Sponsor To Make Additional Contributions To Trust Account Upon Approval Of Proposed Extension AmendmentBiotech Acquisition Company (NASDAQ:BIOT) (the "Company"), a publicly traded special purpose acquisition company, today announced that in connection with a proposed extension (the "Extension") of the time period the Company has to complete an initial business combination, as described in the Proxy Statement (as defined below), IREEM LLC, which has entered into an agreement to acquire the current sponsor's interest in the Company (as described in the Proxy Statement), will deposit into the Company's trust account (the "Trust Account") for each additional month the lesser of (i) an aggregate of $457,500 or (ii) $0.055 per share that remains outstanding and is not redeemed in connection with t
- PRBiotech Acquisition Company Announces Plan for New Sponsor to Make Additional Contributions to Trust Account Upon Approval of Proposed Extension AmendmentNEW YORK, Jan. 4, 2023 /PRNewswire/ -- Biotech Acquisition Company (NASDAQ:BIOT) (the "Company"), a publicly traded special purpose acquisition company, today announced that in connection with a proposed extension (the "Extension") of the time period the Company has to complete an initial business combination, as described in the Proxy Statement (as defined below), IREEM LLC, which has entered into an agreement to acquire the current sponsor's interest in the Company (as described in the Proxy Statement), will deposit into the Company's trust account (the "Trust Account") for each additional month the lesser of (i) an aggregate of $457,500 or (ii) $0.055 per share that remains outstanding an
- SECSEC Form DEF 14A filed by Biotech Acquisition CompanyDEF 14A - Biotech Acquisition Co (0001825413) (Filer)
- SECBiotech Acquisition Company filed SEC Form 8-K: Entry into a Material Definitive Agreement8-K - Biotech Acquisition Co (0001825413) (Filer)
- SECSEC Form PRE 14A filed by Biotech Acquisition CompanyPRE 14A - Biotech Acquisition Co (0001825413) (Filer)
- SECSEC Form NT 10-Q filed by Biotech Acquisition CompanyNT 10-Q - Biotech Acquisition Co (0001825413) (Filer)
BIOT FAQ
6 questionsWhat does Biotech Acquisition Company do?
Biotech Acquisition Company does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.Where does BIOT stock trade?
Biotech Acquisition Company (BIOT) is listed on NASDAQ.What sector and industry is BIOT in?
Biotech Acquisition Company operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Biotech Acquisition Company go public?
Biotech Acquisition Company (BIOT) completed its IPO in 2021.What companies are similar to BIOT?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare BIOT side-by-side with any of them on Quantisnow.How can I track BIOT on Quantisnow?
Quantisnow aggregates Biotech Acquisition Company's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BIOT to receive live email and push alerts on every new disclosure.